Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination

The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma. It will also further observe and learn about the safety of the Bimatoprost Implant System / IOL Combination. The main questions it aims to answer are: * Does the Bimatoprost Implant System / IOL Combination continue lower the pressure inside the eye to treat ocular hypertension or glaucoma long term? * Does the Bimatoprost Implant System / IOL Combination continue to correct vision after cataract surgery long term? * What long term medical problems do participants have when treated with the Bimatoprost Implant System / IOL Combination?

NCT Number	NCT07154810
Lead Sponsor	SpyGlass Pharma, Inc.
Conditions	Glaucoma, Cataract, Ocular Hypertension
Enrollment	23 participants
Start Date	2023-03-16
Primary Completion	2031-04-14 (estimated)
Study Completion	2031-04-14 (estimated)
Updated on ClinicalTrials.gov	2025-09-04